Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice

Chemical Research in Toxicology

Volumn 27, Issue 10, 2014, Pages 1871-1876

  Narayanapillai, Sreekanth C ^a   Leitzman, Pablo ^a   O'Sullivan, M Gerard ^b,c   Xing, Chengguo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHALCONE DERIVATIVE; DIHYDROMETHYSTICIN; FLAVOKAWAIN A; FLAVOKAWAIN B; KAVA; PARACETAMOL; UNCLASSIFIED DRUG; 7,8-DIHYDROMETHYSTICIN; CHALCONE; FLAVONOID; PYRONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; FEMALE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; LIVER; METABOLISM; PATHOLOGY;

ACETAMINOPHEN; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CHALCONE; DRUG SYNERGISM; FEMALE; FLAVONOIDS; KAVA; LIVER; MICE; MICE, INBRED C57BL; PYRONES;

EID: 84908145863     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx5003194     Document Type: Article

References (30)

1. Gounder, R. (2006) Kava consumption and its health effects. Pacific Health Dialogue 13, 131-135.
2. LaPorte, E., Sarris, J., Stough, C., and Scholey, A. (2011) Neurocognitive effects of kava (Piper methysticum): a systematic review. Hum. Psychopharmacol. 26, 102-111.
3. Sarris, J., Kavanagh, D. J., Deed, G., and Bone, K. M. (2009) St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum. Psychopharmacol. 24, 41-48.
4. Sarris, J., Kavanagh, D. J., Byrne, G., Bone, K. M., Adams, J., and Deed, G. (2009) The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl.) 205, 399-407.
5. Pittler, M. H., and Ernst, E. (2000) Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J. Clin. Psychopharmacol. 20, 84-89.
6. Teschke, R., and Wolff, A. (2009) Kava hepatotoxicity: regulatory data selection and causality assessment. Dig. Liver Dis. 41, 891-901.
7. Teschke, R., Sarris, J., and Lebot, V. (2013) Contaminant hepatotoxins as culprits for kava hepatotoxicity-fact or fiction? Phytother. Res. 27, 472-474.
8. Carreño, I., Laurenza, E., Martelloni, A., Salas, B., Simões, B. G., and Vergona, P. R. (2014) German court repeals the withdrawal of marketing authorisation of kava-containing medicinal products. Trade Perspectives 13, 2-5.
9. Schulze, J., Raasch, W., and Siegers, C. P. (2003) Toxicity of kava pyrones, drug safety and precautions - a case study. Phytomedicine 10, 68-73.
10. Anke, J., and Ramzan, I. (2004) Kava Hepatotoxicity: Are we any closer to the truth? Planta Med. 70, 193-196.
11. Lebot, V., Do, T. K., and Legendre, L. (2014) Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem. 151, 554-560.
12. Shaik, A. A., Hermanson, D. L., and Xing, C. (2009) Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity. Bioorg. Med. Chem. Lett. 19, 5732-5736.
13. Leitzman, P., Narayanapillai, S. C., Balbo, S., Zhou, B., Upadhyaya, P., Shaik, A. A., O'Sullivan, M. G., Hecht, S. S., Lu, J., and Xing, C. (2014) Kava Blocks 4-(Methylnitrosamino)-1-(3-pyridyl)-1-Butanone-Induced Lung Tumorigenesis in Association with Reducing O6-methylguanine DNA Adduct in A/J Mice. Cancer Prev. Res. (Phila.) 7, 86-96.
14. W. H. Organization. (2007) Assessments of the risk of hepatotoxicity with kava products. WHO Document Production Service.
15. Teschke, R., Schwarzenboeck, A., and Hennermann, K. H. (2008) Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 20, 1182-1193.
16. Steiner, G. G. (2000) The correlation between cancer incidence and kava consumption. Hawaii Med. J. 59, 420-422.
17. Johnson, T. E., Hermanson, D., Wang, L., Kassie, F., Upadhyaya, P., O'Sullivan, M. G., Hecht, S. S., Lu, J., and Xing, C. (2011) Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. Am. J. Chin. Med. 39, 727-742.
18. Johnson, T. E., Kassie, F., O'Sullivan, M. G., Negia, M., Hanson, T. E., Upadhyaya, P., Ruvolo, P. P., Hecht, S. S., and Xing, C. (2008) Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Cancer Prev. Res. (Phila.) 1, 430-438.
19. Triolet, J., Shaik, A. A., Gallaher, D. D., O'Sullivan, M. G., and Xing, C. (2012) Reduction in colon cancer risk by consumption of kava or kava fractions in carcinogen-treated rats. Nutr. Cancer 64, 838-846.
20. Zi, X., and Simoneau, A. R. (2005) Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice. Cancer Res. 65, 3479-3486.
21. Narayanapillai, S. C., Balbo, S., Leitzman, P., Grill, A. E., Upadhyaya, P., Shaik, A. A., Zhou, B., O'Sullivan, M. G., Peterson, L., Lu, J., Hecht, S. S., and Xing, C. (2014) Dihydromethysticin (DHM) from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. Carcinogenesis,
22. Martin, A. C. J. E., Xing, C., and Hegeman, A. D. (2014) Measuring the chemical and cytotoxic variability of commercially available kava. PLoS One,.
23. National Toxicology Program. (2012) Toxicology and carcinogenesis studies of kava kava extract (CAS No. 9000-38-8) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl. Toxicol. Program Tech. Rep. Ser., 1-186.
24. Yang, X., and Salminen, W. F. (2011) Kava extract, an herbal alternative for anxiety relief, potentiates acetaminophen-induced cytotoxicity in rat hepatic cells. Phytomedicine 18, 592-600.
25. Jhoo, J. W., Freeman, J. P., Heinze, T. M., Moody, J. D., Schnackenberg, L. K., Beger, R. D., Dragull, K., Tang, C. S., and Ang, C. Y. (2006) In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). J. Agric. Food Chem. 54, 3157-3162.
26. DiSilvestro, R. A., Zhang, W., and DiSilvestro, D. J. (2007) Kava feeding in rats does not cause liver injury nor enhance galactosamineinduced hepatitis. Food Chem. Toxicol. 45, 1293-1300.
27. Guo, L., Li, Q., Xia, Q., Dial, S., Chan, P. C., and Fu, P. (2009) Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem. Toxicol. 47, 433-442.
28. Guo, L., Shi, Q., Dial, S., Xia, Q., Mei, N., Li, Q. Z., Chan, P. C., and Fu, P. (2010) Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies - changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. Food Chem. Toxicol. 48, 686-696.
29. Sorrentino, L., Capasso, A., and Schmidt, M. (2006) Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. Phytomedicine 13, 542-549.
30. Zhou, P., Gross, S., Liu, J. H., Yu, B. Y., Feng, L. L., Nolta, J., Sharma, V., Piwnica-Worms, D., and Qiu, S. X. (2010) Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B and MAPK signaling pathways. FASEB J. 24, 4722-4732.